---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-002745"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:28:11.826081+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Cullinan Oncology reports $468.3M cash as of Dec 31, 2023; runway into H2 2026

## Summary
- Unaudited cash, equivalents, investments, and interest receivable totaled $468.3M as of Dec 31, 2023.
- Company expects cash runway into second half of 2026 under current operating plan.
- Preliminary figure subject to change upon completion of financial closing procedures.

## SEC filing metadata
- accession: 0000950170-24-002745
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000095017024002745/0000950170-24-002745-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000095017024002745/cgem-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-002745
- JSON: https://secwatch.observer/filing/0000950170-24-002745.json
- Plain text: https://secwatch.observer/filing/0000950170-24-002745.txt

## Key facts
- Earnings Releases
  Cullinan Therapeutics, Inc. updated its quarter ended December 31, 2023 guidance (reaffirmed).
  - Period: quarter ended December 31, 2023
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: As of December 31, 2023, Cullinan Oncology, Inc.’s (the “Company’s”) unaudited cash, cash equivalents, investments, and interest receivable totaled $468.3 million. Consistent with prior guidance, the Company expects its cash resources to provide runway into the second half of 2026 based on its current operating plan. The Company has not yet completed its quarter-end financial close process for the quarter ended December 31, 2023. This estimate of the Company’s cash, cash equivalents, investments, and interest receivable as of December 31, 2023 is preliminary, has not been audited and is subject to change upon completion of the Company’s financial statement closing procedures.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789972/000095017024002745/0000950170-24-002745-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.